Patent ID: 9082145
Filing Date: 2015-07-14
Classification: B01J,C40B,G06Q,G16H

Abstract:
1. A process for improving the identification and administration of safer products, including cells and cell-derived products for administration to subscribers, such that the products identified entail a lower risk of adverse reactions or adverse outcomes when administered to a subscriber, wherein the process accommodates additional clinically significant attributes, once these are determined to be significant, comprising the following steps: a. storing a unique subscriber identifier in a device controlled by the subscriber; b. generating and updating an encrypted molecular signature for the subscriber by: c. receiving or obtaining the profile of the clinically significant attributes of candidate products to be administered to the subscriber; and d. analyzing the similarities and differences between the subscriber's molecular signature and the profile of the products to be administered to said subscriber, and administering products which either: do not contain any clinically significant attributes which the subscriber does not also express; or contain some clinically significant attributes which the subscriber does not express but said some clinically significant attributes do not render the product unacceptably unsafe based on the anticipated severity of the adverse subscriber reaction or adverse clinical outcome; and e. receiving at a website a request from a patient or the patient's designee for products suitable for being administered to the patient, and the patient identifier and encrypted molecule signature; authenticating the patient identifier; decoding the signature to recover the molecular signature, and transmitting to the authenticated requestor the attributes of products suitable for being administered to the patient.